EC 1169

Drug Profile

EC 1169

Alternative Names: DUPA-TubH III; EC 1719; EC-1069; EC1169; PSMA-Tubulysin

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endocyte
  • Class Antineoplastics; Biological toxins; Drug conjugates; Peptides; Small molecules
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Prostate-cancer(Late-stage disease, Recurrent, Second-line therapy or greater) in USA (IV, Injection)
  • 08 Sep 2017 Updated efficacy and adverse events data from a phase I trial in Prostate cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 02 Jun 2017 Efficacy and adverse events data from a phase-I trial in Prostate cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top